About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The group of Clinical Neuroimmunology - Centre d'Esclerosi Múltiple de Catalunya (Cemcat) at the Vall d'Hebron Institut de Recerca (VHIR) is a multidisciplinary group dedicated to clinical assistance, physical and cognitive rehabilitation, and clinical and basic research on multiple sclerosis (MS). Cemcat is a national but also an international reference center in the clinical assistance of MS patients. The research performed in the group is divided and further combined in clinical and basic research. In addition, basic research has a marked translational character since the ultimate goal of the group is to improve the quality of life of patients suffering from MS, through in-depth knowledge of the pathogenic mechanisms of the disease and the development of new and more effective therapeutic approaches.
PMID: 37841069 Journal: Brain communications Year: 2023 Reference: Brain Commun. 2023 Oct 4;5(5):fcad255. doi: 10.1093/braincomms/fcad255. eCollection 2023. Impact factor: Publication type: Paper in international publication Authors: Barkhof, Frederik; Brownlee, Wallace; Castano, Carlos; Chard, Declan; Chung, Karen; Ciccarelli, Olga; Dominguez, Carlos; Gandini Wheeler-Kingshott, Claudia A M; Gramegna, Laura Ludovica; Haider, Lukas et al. DOI: 10.1093/braincomms/fcad255
PMID: 37841253 Journal: Frontiers in Immunology Year: 2023 Reference: Front Immunol. 2023 Sep 29;14:1248182. doi: 10.3389/fimmu.2023.1248182. eCollection 2023. Impact factor: Publication type: Paper in international publication Authors: Aladro, Yolanda; Alia, Eva Maria Guerra; Alvarez-Lafuente, Roberto; Arroyo, Rafael; Baurain, Jean-Francois; Braicu, Elena Ioana; Casanova-Peno, Ignacio; Colombo, Nicoletta; Comabella, Manuel; Costa-Frossard, Lucienne et al. DOI: 10.3389/fimmu.2023.1248182
PMID: 37850411 Journal: JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY Year: 2023 Reference: J Investig Allergol Clin Immunol. 2023 Oct 18:0. doi: 10.18176/jiaci.0941. Impact factor: Publication type: Paper in international publication Authors: Aladro, Yolanda; Alvarez-Lafuente, Roberto; Arroyo, Rafael; Casanova-Peno, Ignacio; Comabella, Manuel; Costa-Frossard, Lucienne; Cruz, M J; Dominguez-Mozo, Maria Inmaculada; Espejo, D; Garcia-Dominguez, Jose Manuel et al. DOI: 10.18176/jiaci.0941
PMID: 37850363 Journal: Future Oncology Year: 2023 Reference: Future Oncol. 2023 Oct 18. doi: 10.2217/fon-2023-0282. Impact factor: Publication type: Paper in international publication Authors: Barkhof, Frederik; Bokemeyer, Carsten; Brownlee, Wallace; Chard, Declan; Chung, Karen; Ciardiello, Fortunato; Ciccarelli, Olga; Dubreuil, Olivier; Esser, Regina; Gandini Wheeler-Kingshott, Claudia A M et al. DOI: 10.2217/fon-2023-0282
PMID: 35084734 Journal: REVISTA DE NEUROLOGIA Year: 2022 Reference: Rev Neurol. 2022 Feb 1;74(3):93-104. doi: 10.33588/rn.7403.2021473. Impact factor: 0.87 Publication type: Review in national publication Authors: Rodriguez-Acevedo, B, Rovira, A, Vidal-Jordana, A, Moncho, D, Pareto, D, Sastre-Garriga, J et al. DOI: 10.33588/rn.7403.2021473
PMID: 35067066 Journal: Multiple Sclerosis Journal Year: 2022 Reference: Mult Scler. 2022 Mar;28(3):357-358. doi: 10.1177/13524585211069363. Epub 2022 Jan 22. Impact factor: 6.312 Publication type: Letter or abstract Authors: Rovira, Alex, Pareto, Deborah et al. DOI: 10.1177/13524585211069363
PMID: 35048162 Journal: NEURORADIOLOGY Year: 2022 Reference: Neuroradiology. 2022 Jul;64(7):1383-1390. doi: 10.1007/s00234-021-02885-7. Epub 2022 Jan 20. Impact factor: 2.804 Publication type: Paper in international publication Authors: Pareto, Deborah, Garcia-Vidal, Aran, Groppa, Sergiu, Gonzalez-Escamilla, Gabriel, Rocca, Mara, Filippi, Massimo, Enzinger, Christian, Khalil, Michael, Llufriu, Sara, Sastre-Garriga, Jaume et al. DOI: 10.1007/s00234-021-02885-7
PMID: 34711650 Journal: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY Year: 2022 Reference: J Neurol Neurosurg Psychiatry. 2022 Feb;93(2):188-195. doi: 10.1136/jnnp-2021-327412. Epub 2021 Oct 28. Impact factor: 10.283 Publication type: Paper in international publication Authors: Radaelli, Marta, Lu, Angelo, Zimmermann, Hanna G, Specovius, Svenja, Motamedi, Seyedamirhosein, Chien, Claudia, Bereuter, Charlotte, Lana-Peixoto, Marco A, Fontenelle, Mariana Andrade, Ashtari, Fereshteh et al. DOI: 10.1136/jnnp-2021-327412
In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.
Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.
The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.
Simoa HD1 equipment
We are looking for 100 healthy volunteers aged 18 or over to participate in a project where the usefulness of biomarkers in serum will be evaluated to predict the prognosis of the disease and the response to treatments.
